ADVERTISEMENT

Conference Report

ISCHEMIA-EXTEND: Conservative Stable CAD Management Holds Up

Mitchel Zoler   |   07 November 2022

CHICAGO – The case for survival equipoise between an invasive or conservative strategy for managing patients with stable coronary disease and moderate or severe cardiac ischemia grew stronger with an additional 2.5 years of median follow-up of the landmark ISCHEMIA trial.

During a median follow-up of 5.7 years in ISCHEMIA-EXTEND – and as long...

          

November Challenge

Ends in 11h
left
right

Topic Challenges

left
right